[Key Financial Data and Indicators](index=1&type=section&id=I.%20Key%20Financial%20Data%20and%20Indicators%20for%20the%20First%20Half%20of%202025) In the first half of 2025, Qingdao Bank achieved robust performance growth with revenue up 7.50% and net profit attributable to shareholders up 16.05%, while total assets expanded by 7.69% and asset quality improved with non-performing loan ratio decreasing to 1.12% and provision coverage ratio increasing to 252.80% Key Financial Data and Indicators | Item | Jan-Jun 2025 (Thousand Yuan) | Jan-Jun 2024 (Thousand Yuan) | Change (%) | | :--- | :--- | :--- | :--- | | **Operating Revenue** | 7,662,414 | 7,128,085 | 7.50% | | **Net Profit Attributable to Parent Company Shareholders** | 3,064,683 | 2,640,917 | 16.05% | | **Basic Earnings Per Share (Yuan/share)** | 0.53 | 0.45 | 17.78% | | **Weighted Average Return on Net Assets (Annualized, %)** | 15.75% | 15.34% | Increased by 0.41 percentage points | | **Item** | **As of Jun 30, 2025 (Thousand Yuan)** | **As of Dec 31, 2024 (Thousand Yuan)** | **Change (%)** | | **Total Assets** | 743,027,546 | 689,963,033 | 7.69% | | **Equity Attributable to Parent Company Shareholders** | 46,078,064 | 43,932,381 | 4.88% | | **Non-Performing Loan Ratio (%)** | 1.12% | 1.14% | Decreased by 0.02 percentage points | | **Provision Coverage Ratio (%)** | 252.80% | 241.32% | Increased by 11.48 percentage points | [Explanation of Operating Performance and Financial Condition](index=2&type=section&id=II.%20Explanation%20of%20Operating%20Performance%20and%20Financial%20Condition) In the first half of 2025, the company adhered to its annual operating philosophy of 'professional enhancement, digital empowerment, system optimization, and distinctive drive,' actively implementing key financial initiatives to achieve simultaneous improvements in business scale, operating efficiency, and asset quality - The company fully implemented central, provincial, and municipal strategic deployments, committed to high-quality development, and further advanced key financial initiatives[5](index=5&type=chunk) [Steady Growth in Operating Scale](index=2&type=section&id=Steady%20Growth%20in%20Operating%20Scale) As of June 2025, the company's business scale steadily expanded, with total assets reaching **743.028 billion yuan**, a 7.69% increase from year-end, and customer loans and deposits growing by 8.14% and 7.90% respectively Operating Scale Growth | Item | As of Jun 2025 (Billion Yuan) | Growth Rate vs. Year-End (%) | | :--- | :--- | :--- | | **Total Assets** | 743.028 | 7.69% | | **Total Customer Loans** | 368.406 | 8.14% | | **Total Liabilities** | 695.944 | 7.89% | | **Total Customer Deposits** | 466.140 | 7.90% | [Robust Improvement in Profitability](index=2&type=section&id=Robust%20Improvement%20in%20Profitability) In the first half of 2025, the company's profitability significantly strengthened, with net profit attributable to parent company shareholders and operating revenue growing by 16.05% and 7.50% respectively, and basic earnings per share increasing by 17.78% to **0.53 yuan** Profitability Indicators | Indicator | First Half 2025 (Billion Yuan) | Year-over-Year Growth | | :--- | :--- | :--- | | **Net Profit Attributable to Parent Company Shareholders** | 3.065 | 16.05% | | **Operating Revenue** | 7.662 | 7.50% | | **Weighted Average Return on Net Assets (Annualized)** | 15.75% | Increased by 0.41 percentage points | | **Basic Earnings Per Share (Yuan)** | 0.53 | 17.78% | [Continued Improvement in Asset Quality](index=2&type=section&id=Continued%20Improvement%20in%20Asset%20Quality) As of June 2025, the company's asset quality continued to improve, with the non-performing loan ratio decreasing by **0.02 percentage points** to **1.12%**, and risk coverage strengthening as the provision coverage ratio increased by **11.48 percentage points** to **252.80%** Asset Quality Indicators | Indicator | As of Jun 2025 | Change vs. Year-End | | :--- | :--- | :--- | | **Non-Performing Loan Ratio** | 1.12% | Decreased by 0.02 percentage points | | **Provision Coverage Ratio** | 252.80% | Increased by 11.48 percentage points | [Reference Documents](index=2&type=section&id=III.%20Reference%20Documents) The reference documents for this performance express report include comparative balance sheets and income statements signed and sealed by the company's senior management, including the legal representative, president, vice president in charge of finance, and general manager of the finance department - Reference documents include comparative balance sheets and income statements signed and sealed by the bank's current legal representative and Chairman Mr. Jing Zailun, President Mr. Wu Xianming, Vice President in charge of finance Ms. Chen Shuang, and General Manager of the Planning and Finance Department Mr. Li Zhendong[7](index=7&type=chunk)

[Important Notes, Table of Contents and Definitions](index=2&type=section&id=Item%201.%20Important%20Notes%2C%20Table%20of%20Contents%20and%20Definitions) [Important Notes](index=2&type=section&id=Important%20Notes) The company's board of directors, audit committee, and all senior executives guarantee the truthfulness, accuracy, and completeness of this semi-annual report, assuming legal responsibility for no false statements, misleading representations, or material omissions - Company management ensures the truthfulness, accuracy, and completeness of the report, assuming corresponding legal responsibilities[4](index=4&type=chunk) [Risk Warnings](index=2&type=section&id=Risk%20Warnings) The company faces five main risks: raw material price fluctuations, product price declines, technology substitution, industry overcapacity, and macroeconomic and policy changes - The company faces key operational risks including: - **Raw Material Price Volatility Risk**: Fluctuations in primary graphite and coke raw material prices may impact the company's profitability[5](index=5&type=chunk) - **Product Price Decline Risk**: Intense market competition, changes in downstream demand, and industry cost reduction trends may lead to lower anode material prices[6](index=6&type=chunk)[7](index=7&type=chunk) - **Technology Substitution Risk**: If the company's R&D lags behind the development of new battery material technologies, it may adversely affect future operations[8](index=8&type=chunk) - **Overcapacity Risk**: Industry expansion and new entrants may lead to slower-than-expected market demand growth and overcapacity[9](index=9&type=chunk) - **Macroeconomic and Policy Change Risk**: Adjustments in new energy industry policies and macroeconomic uncertainties may affect the company's performance[10](index=10&type=chunk)[11](index=11&type=chunk) [Profit Distribution Plan](index=4&type=section&id=Profit%20Distribution%20Plan) The company plans no cash dividends, bonus shares, or capital increase from capital reserves for the 2025 semi-annual period - The company has no plans for cash dividends or share transfers during this reporting period[12](index=12&type=chunk) [Definitions](index=7&type=section&id=Definitions) This section defines professional terms used in the report, covering company entities, key customers, lithium battery industry technologies, and critical performance indicators [Company Profile and Key Financial Indicators](index=9&type=section&id=Item%202.%20Company%20Profile%20and%20Key%20Financial%20Indicators) [Company Profile](index=9&type=section&id=Company%20Profile) Shanghai Xiangfenghua Technology Co Ltd (stock code 300890) is a Shenzhen Stock Exchange-listed company primarily engaged in the R&D, production, and sales of lithium battery anode materials Company Information | Item | Content | | :--- | :--- | | **Stock Abbreviation** | Xiangfenghua | | **Stock Code** | 300890 | | **Listing Exchange** | Shenzhen Stock Exchange | | **Company Name** | Shanghai Xiangfenghua Technology Co Ltd | | **Legal Representative** | Zhao Donghui | [Key Accounting Data and Financial Indicators](index=10&type=section&id=Key%20Accounting%20Data%20and%20Financial%20Indicators) During the reporting period, the company's operating revenue decreased by 2.80% to RMB 687.59 million, resulting in a net loss of RMB 2.95 million due to product price declines, and operating cash flow significantly decreased by 364.68% Key Financial Indicators | Key Financial Indicators | Current Reporting Period (RMB) | Prior Year Period (RMB) | YoY Change | | :--- | :--- | :--- | :--- | | **Operating Revenue** | 687,591,351.12 | 707,372,276.94 | -2.80% | | **Net Profit Attributable to Shareholders** | -2,945,933.47 | 38,240,844.00 | -107.70% | | **Net Profit Excluding Non-Recurring Items** | -14,797,234.41 | 24,807,682.81 | -159.65% | | **Net Cash Flow from Operating Activities** | -181,443,834.19 | 68,551,196.79 | -364.68% | | **Basic Earnings Per Share (RMB/share)** | -0.0247 | 0.3497 | -107.06% | | **Weighted Average Return on Net Assets** | -0.14% | 1.99% | -2.13% | | **Total Assets** | 4,711,012,343.51 | 4,436,207,714.82 (End of Prior Year) | 6.19% | [Non-Recurring Gains and Losses Items and Amounts](index=11&type=section&id=Non-Recurring%20Gains%20and%20Losses%20Items%20and%20Amounts) During the reporting period, the company's non-recurring gains and losses totaled RMB 11.85 million, primarily from government subsidies and other non-operating income and expenses Non-Recurring Gains and Losses | Item | Amount (RMB) | | :--- | :--- | | Government subsidies included in current profit/loss | 8,773,118.80 | | Fair value changes in financial assets/liabilities | 841,748.38 | | Net other non-operating income and expenses | 4,471,847.50 | | **Total** | **11,851,300.94** | [Management Discussion and Analysis](index=12&type=section&id=Item%203.%20Management%20Discussion%20and%20Analysis) [Main Businesses of the Company During the Reporting Period](index=12&type=section&id=I.%20Main%20Businesses%20of%20the%20Company%20During%20the%20Reporting%20Period) The company's core business is the R&D, production, and sales of lithium battery anode materials, with graphite anode materials widely used in power, 3C consumer electronics, and industrial energy storage - The company's core business is graphite anode materials, applied in new energy vehicles, consumer electronics, and energy storage sectors[35](index=35&type=chunk) - The company operates a mature and stable business model, primarily based on production-to-order and direct sales[35](index=35&type=chunk) Key Financial Performance | Financial Indicator | H1 2025 | YoY Change | | :--- | :--- | :--- | | **Operating Revenue** | RMB 688 million | -2.80% | | **Net Profit Attributable to Parent** | RMB -2.95 million | -107.70% | - Performance decline is primarily due to a temporary supply-demand imbalance in the graphite anode material industry, intense market competition, leading to product price reductions and lower gross margins[38](index=38&type=chunk) [Core Competitiveness Analysis](index=13&type=section&id=II.%20Core%20Competitiveness%20Analysis) The company's core competitiveness stems from its technological R&D, core team, and customer resources, including 71 authorized invention patents and strategic partnerships - **Technology and R&D Advantages**: The company boasts a complete product line, adheres to a technology roadmap emphasizing both artificial and natural graphite, holds 71 authorized invention patents as of the reporting period end, and collaborates with universities like Tsinghua University Shenzhen Graduate School for industry-academia-research initiatives[39](index=39&type=chunk)[40](index=40&type=chunk) - **Core Team Advantages**: The core management team, led by individuals with materials science backgrounds from Tsinghua University, possesses over a decade of experience in lithium battery materials[40](index=40&type=chunk) - **Customer Advantages**: The company has cultivated high-quality clients such as LG Energy Solution, Gotion High-tech, and BYD, while actively expanding into international markets including PowerCo SE (Germany) and SK on (South Korea)[41](index=41&type=chunk) [Main Business Analysis](index=14&type=section&id=III.%20Main%20Business%20Analysis) During the reporting period, the company's anode material revenue decreased by 3.04% to RMB 684.12 million, with gross margin falling by 6.23 percentage points to 12.35% due to lower product unit prices Key Financial Data Changes | Key Financial Data | Current Reporting Period (RMB) | Prior Year Period (RMB) | YoY Change | Reason for Change | | :--- | :--- | :--- | :--- | :--- | | **Operating Revenue** | 687,591,351.12 | 707,372,276.94 | -2.80% | Increased industry competition, lower product unit prices | | **Selling Expenses** | 13,440,556.54 | 21,549,360.75 | -37.63% | Decrease in business expenses | | **Net Cash Flow from Operating Activities** | -181,443,834.19 | 68,551,196.79 | -364.68% | Decrease in customer cash collections | | **Net Cash Flow from Financing Activities** | 365,011,050.18 | -172,665,603.14 | -311.40% | Increase in bank borrowings | | **Construction in Progress** | 557,419,741.40 | 361,496,966.29 | 54.20% | Construction of Shanghai North-South Zone projects | | **Short-term Borrowings** | 566,688,381.64 | 331,492,332.21 | 70.95% | Increase in bank borrowings | | **Long-term Borrowings** | 586,156,378.93 | 398,511,626.03 | 47.09% | Increase in special loans for Shanghai North-South Zone construction | Revenue and Gross Margin by Product | By Product | Operating Revenue (RMB) | Operating Cost (RMB) | Gross Margin | YoY Operating Revenue Change | YoY Gross Margin Change | | :--- | :--- | :--- | :--- | :--- | :--- | | **Anode Materials** | 684,122,026.46 | 599,624,124.87 | 12.35% | -3.04% | -6.23% | [Analysis of Assets and Liabilities](index=16&type=section&id=V.%20Analysis%20of%20Assets%20and%20Liabilities) As of the reporting period end, the company's total assets were RMB 4.71 billion, a 6.19% increase from the end of the previous year, with significant growth in construction in progress and borrowings - Construction in progress balance at period-end was **RMB 557.42 million**, a 54.20% increase from the end of the previous year, primarily due to investment in the Shanghai North-South Zone engineering projects[52](index=52&type=chunk) - Short-term and long-term borrowings at period-end were **RMB 566.69 million** and **RMB 586.16 million** respectively, increasing by 70.95% and 47.09% from the end of the previous year, mainly due to increased bank borrowings[52](index=52&type=chunk) Restricted Assets | Item | Book Value at Period-End (RMB) | Restriction Status | | :--- | :--- | :--- | | **Monetary Funds** | 115,286,173.04 | Deposits and frozen funds | | **Notes Receivable** | 51,564,385.23 | Pledged | | **Fixed Assets** | 129,392,466.54 | Loan collateral | | **Intangible Assets** | 174,678,904.13 | Loan collateral | | **Construction in Progress** | 485,631,032.93 | Loan collateral | | **Total** | **956,552,961.87** | / | [Investment Analysis](index=19&type=section&id=VI.%20Investment%20Analysis) During the reporting period, the company's investment amounted to RMB 862 million, a 7.48% year-on-year increase, primarily focused on significant non-equity projects like R&D center construction and production bases - The investment amount for the reporting period was **RMB 862 million**, a 7.48% year-on-year increase[58](index=58&type=chunk) Major Non-Equity Investment Projects | Major Non-Equity Investment Project | Amount Invested in Current Period (RMB) | Cumulative Investment as of Period-End (RMB) | Project Progress | | :--- | :--- | :--- | :--- | | **R&D Center Construction Project** | 28,131,301.00 | 113,712,466.00 | 90.97% | | **60,000-ton Artificial Graphite Anode Material Integrated Production Base** | 34,260,246.45 | 228,566,908.44 | 66.91% | | **Shanghai Tanfeng Sci-Tech Innovation Center** | 177,733,150.82 | 467,430,002.63 | 27.48% | - Progress of raised capital projects has slowed due to objective factors: - **R&D Center Construction Project**: The original implementation site's building load-bearing capacity was insufficient, so the location was changed to Shanghai Tanfeng Sci-Tech Innovation Industrial Park, with an estimated completion time extended to July 2026[72](index=72&type=chunk) - **60,000-ton Artificial Graphite Anode Material Integrated Production Base Project**: Due to delays in land supply, the estimated completion time has been extended to December 2026[72](index=72&type=chunk)[73](index=73&type=chunk) [Analysis of Major Holding and Participating Companies](index=27&type=section&id=VIII.%20Analysis%20of%20Major%20Holding%20and%20Participating%20Companies) The company's major subsidiaries include Fujian Xiangfenghua and Sichuan Xiangfenghua, with Fujian Xiangfenghua being the primary production base and Sichuan Xiangfenghua under construction Major Subsidiaries' Financial Performance (H1 2025) | Major Subsidiary | Total Assets (RMB ten thousand) | Net Assets (RMB ten thousand) | Operating Revenue (RMB ten thousand) | Net Profit (RMB ten thousand) | | :--- | :--- | :--- | :--- | :--- | | **Fujian Xiangfenghua** | 313,918.61 | 129,460.04 | 66,861.86 | 710.49 | | **Sichuan Xiangfenghua** | 103,351.55 | 29,593.36 | 10,898.85 | -243.60 | | **Hainan Xiangfenghua** | 15,405.40 | 7,304.45 | 11,999.52 | 1,402.66 | | **Shanghai Xiangfenghua** | 72,565.18 | 20,333.42 | 0.00 | -97.60 | - On July 25, 2025, the company established a new controlling subsidiary, "Sichuan Xiangzhan Zhenhua New Material Technology Co Ltd," with the company holding 60% equity, primarily engaged in new material technology R&D, graphite and carbon product manufacturing, and sales[86](index=86&type=chunk)[87](index=87&type=chunk) [Corporate Governance, Environment and Society](index=33&type=section&id=Item%204.%20Corporate%20Governance%2C%20Environment%20and%20Society) [Changes in Directors, Supervisors, and Senior Management](index=33&type=section&id=I.%20Changes%20in%20Directors%2C%20Supervisors%2C%20and%20Senior%20Management) During the reporting period, the company underwent a board and supervisory board re-election on June 30, 2025, leading to changes in several directors, supervisors, and senior management positions - On June 30, 2025, due to re-election, several directors, supervisors, and senior management personnel changed, including the election of Zhou Pengwei as Chairman and Zhao Donghui as Vice Chairman and General Manager[95](index=95&type=chunk) - The company plans no cash dividends, bonus shares, or capital increase from capital reserves for the semi-annual period[96](index=96&type=chunk) [Environmental Information Disclosure](index=35&type=section&id=IV.%20Environmental%20Information%20Disclosure) The company and its major subsidiaries are not included in the list of enterprises required to disclose environmental information by law, but actively fulfill social responsibilities - The company actively fulfills its social responsibilities, donating **RMB 1 million** to the Tsinghua University Education Foundation in the first half of the year and providing local employment opportunities[98](index=98&type=chunk) [Significant Matters](index=36&type=section&id=Item%205.%20Significant%20Matters) [Commitments Fulfilled and Overdue Unfulfilled Commitments by Controlling Shareholders, Shareholders, Related Parties, Acquirers, and the Company](index=36&type=section&id=I.%20Commitments%20Fulfilled%20and%20Overdue%20Unfulfilled%20Commitments%20by%20Controlling%20Shareholders%2C%20Shareholders%2C%20Related%20Parties%2C%20Acquirers%2C%20and%20the%20Company) During the reporting period, the company and related parties strictly fulfilled all commitments made during initial public offerings, refinancing, and equity incentive activities, with no violations observed - The company and related parties strictly fulfilled all public commitments during the reporting period, with no violations observed[100](index=100&type=chunk) [Significant Related Party Transactions](index=64&type=section&id=XI.%20Significant%20Related%20Party%20Transactions) During the reporting period, the company engaged in routine related party transactions with Yong'an Dingfeng Carbon Technology Co Ltd, totaling RMB 10.33 million, within the approved annual limit Related Party Transactions | Related Party | Related Transaction Content | Amount Incurred in Current Period (RMB ten thousand) | Approved Transaction Limit (RMB ten thousand) | Exceeded Limit | | :--- | :--- | :--- | :--- | :--- | | Yong'an Dingfeng Carbon Technology Co Ltd | Acceptance of processing services | 739.66 | 2,000 | No | | Yong'an Dingfeng Carbon Technology Co Ltd | Lease of factory buildings and equipment, sale of electricity | 293.00 | 701 | No | [Significant Contracts and Their Performance](index=70&type=section&id=XII.%20Significant%20Contracts%20and%20Their%20Performance) During the reporting period, the company provided significant guarantees for its subsidiaries, with a total approved guarantee limit of RMB 3.10 billion and an actual outstanding guarantee balance of RMB 1.14 billion Guarantee Information | Guarantee Status | Amount (RMB ten thousand) | | :--- | :--- | | **Total approved guarantee limit for subsidiaries at period-end** | 310,099.5 | | **Total actual guarantee balance for subsidiaries at period-end** | 113,989.33 | - The actual total guarantee amount accounts for **52.60%** of the company's net assets[157](index=157&type=chunk) [Changes in Shares and Shareholder Information](index=78&type=section&id=Item%206.%20Changes%20in%20Shares%20and%20Shareholder%20Information) [Changes in Shares](index=78&type=section&id=I.%20Changes%20in%20Shares) During the reporting period, the company's total share capital increased by 673 shares to 119,032,152 shares due to the conversion of "Xiangfeng Convertible Bonds" - During the reporting period, the company's total share capital increased by **673 shares** due to the conversion of "Xiangfeng Convertible Bonds"[163](index=163&type=chunk) Share Capital Changes | Share Class | Quantity Before Change | Quantity After Change | Proportion After Change | | :--- | :--- | :--- | :--- | | **Restricted Shares** | 12,079,360 | 10,438,885 | 8.77% | | **Unrestricted Shares** | 106,952,119 | 108,593,267 | 91.23% | | **Total Share Capital** | **119,031,479** | **119,032,152** | **100.00%** | [Number of Shareholders and Shareholding Information](index=79&type=section&id=III.%20Number%20of%20Shareholders%20and%20Shareholding%20Information) As of the reporting period end, the company had 24,817 common shareholders, with the top ten shareholders' holdings remaining relatively stable - As of the end of the reporting period, the company had a total of **24,817** common shareholders[167](index=167&type=chunk) Top Five Shareholders | Top Five Shareholders | Shareholding Percentage | Shares Held at Period-End | | :--- | :--- | :--- | | Zhou Pengwei | 11.29% | 13,433,514 | | Zhong Yinghao | 5.00% | 5,951,473 | | Lei Zuyun | 2.00% | 2,377,333 | | Huizhou Zhongcheng Zhiyuan Enterprise Management Center | 1.70% | 2,025,913 | | Golden Eagle Fund - Wu Haiyi - Golden Eagle Optimal 196 | 1.61% | 1,916,900 | [Bond-Related Information](index=84&type=section&id=Item%207.%20Bond-Related%20Information) [Convertible Corporate Bonds](index=84&type=section&id=IV.%20Convertible%20Corporate%20Bonds) The company's "Xiangfeng Convertible Bonds" were in their conversion period during the reporting period, with RMB 226.51 million already converted into shares, representing 28.31% of the total issuance - The company's convertible corporate bonds, "Xiangfeng Convertible Bonds" (code 123225), were issued in October 2023, with a total amount of **RMB 800 million** and a term of **6 years**[178](index=178&type=chunk)[562](index=562&type=chunk) Convertible Bond Status | Item | Amount/Quantity | | :--- | :--- | | **Unconverted Amount (RMB)** | 573,488,100.00 | | **Cumulative Converted Amount (RMB)** | 226,511,900.00 | | **Cumulative Converted Shares (shares)** | 8,241,411 | | **Proportion of Unconverted Amount to Total Issuance** | 71.69% | - The conversion price underwent several adjustments during the reporting period, with the latest conversion price at period-end being **RMB 27.44/share**[185](index=185&type=chunk) - China Chengxin International Credit Rating Co Ltd's latest credit rating for the company and its bonds is **AA-**, with a stable outlook[188](index=188&type=chunk) [Financial Report](index=88&type=section&id=Item%208.%20Financial%20Report) [Financial Statements](index=88&type=section&id=Financial%20Statements) This semi-annual financial report is unaudited, presenting consolidated and parent company statements that show steady asset growth but deteriorating profitability and cash flow Consolidated Financial Statement Summary | Consolidated Statement Key Item | Period-End Balance / Current Period Amount (RMB) | | :--- | :--- | | **Total Assets** | 4,711,012,343.51 | | **Total Liabilities** | 2,452,503,616.78 | | **Total Owners' Equity** | 2,258,508,726.73 | | **Total Operating Revenue** | 687,591,351.12 | | **Net Profit** | -3,385,128.92 | | **Net Profit Attributable to Parent Company Owners** | -2,945,933.47 | | **Net Cash Flow from Operating Activities** | -181,443,834.19 | [Consolidated Balance Sheet](index=88&type=section&id=Consolidated%20Balance%20Sheet) As of June 30, 2025, the company's total assets were RMB 4.71 billion, total liabilities RMB 2.45 billion, and owners' equity attributable to the parent company RMB 2.17 billion, with an asset-liability ratio of 52.06% [Consolidated Income Statement](index=92&type=section&id=Consolidated%20Income%20Statement) In the first half of 2025, the company achieved operating revenue of RMB 688 million, with total operating costs of RMB 704 million, resulting in an operating loss of RMB 11.05 million and a net loss of RMB 3.39 million [Consolidated Cash Flow Statement](index=96&type=section&id=Consolidated%20Cash%20Flow%20Statement) During the reporting period, net cash flow from operating activities was RMB -181.44 million, from investing activities RMB -186 million, and from financing activities RMB 365 million, leading to a net decrease in cash and cash equivalents of RMB 2.36 million [Notes to Financial Statements](index=105&type=section&id=Notes%20to%20Financial%20Statements) The financial statement notes detail the company's basic information, financial statement preparation basis, significant accounting policies and estimates, and provide detailed explanations for key items in the consolidated financial statements

2025-065 2025 年 8 月 1 迈克生物股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 迈克生物股份有限公司 2025 年半年度报告全文 迈克生物股份有限公司 2025 年半年度报告 所有董事均已出席了审议本次半年报的董事会会议。 本报告中如有涉及到未来的计划、业绩预测等方面的内容，均不构成本 公司对任何投资者及相关人士的实质承诺，投资者及相关人士均应对此保持 足够的风险认识，并且应当理解计划、预测与承诺之间的差异。 公司可能面临的风险详见本报告"第三节管理层讨论与分析"之"十、 公司面临的风险和应对措施"。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | | | | 第一节 | 重要提示、目录和释义 | 2 | | --- | --- | --- | | 第二节 | 公司简介和主要财务指标 | 7 | | 第三节 | 管理层讨论与分析 | 10 | | 第四节 | 公司治理、环境和社会 | 34 | | 第五节 | 重要事项 | 37 | | 第六节 | 股份变动及股东情况 | 43 | | 第七节 | 债券相关情况 | 49 | | 第八节 | 财务报告 ...

[Current Period Performance Forecast](index=1&type=section&id=I.%20Current%20Period%20Performance%20Forecast) The company forecasts a year-over-year increase in 2025 H1 performance, with net profit attributable to shareholders expected to grow **38.65% to 59.85%** 2025 Semi-Annual Performance Forecast (Compared to Prior Period) | Item | Current Reporting Period (Jan 1 - Jun 30, 2025) | Prior Period | | :--- | :--- | :--- | | **Net Profit Attributable to Shareholders (CNY billion)** | Profit: 1.70 – 1.96 | Profit: 1.23 | | Year-over-Year Growth | 38.65% – 59.85% | - | | **Net Profit Excluding Non-Recurring Gains/Losses (CNY billion)** | Profit: 1.55 – 1.81 | Profit: 1.18 | | Year-over-Year Growth | 31.37% – 53.41% | - | [Communication with Accounting Firm](index=1&type=section&id=II.%20Communication%20with%20Accounting%20Firm) The company's performance forecast is a preliminary internal estimate, not yet audited by an accounting firm - This performance forecast is a preliminary company estimate, unaudited by an accounting firm[4](index=4&type=chunk) [Explanation of Performance Changes](index=1&type=section&id=III.%20Explanation%20of%20Performance%20Changes) Significant performance growth is primarily driven by the continuous and successful revenue recognition of existing orders - The primary driver of performance growth is the continuous acceptance and revenue recognition of existing orders during the reporting period[5](index=5&type=chunk) [Other Relevant Information](index=1&type=section&id=IV.%20Other%20Relevant%20Information) The company reiterates that this unaudited performance forecast is preliminary, advising investors to consider investment risks, with final data in the 2025 semi-annual report - The company reminds investors that this performance forecast is a preliminary estimate, unaudited, and final data will be based on the 2025 semi-annual report, requiring cautious decision-making and attention to investment risks[6](index=6&type=chunk)[7](index=7&type=chunk)

[Important Notice, Table of Contents and Definitions](index=2&type=section&id=Section%201.%20Important%20Notice%2C%20Table%20of%20Contents%20and%20Definitions) This section provides important disclaimers, a table of contents, and definitions of key terms used throughout the report [Important Notice](index=2&type=section&id=Important%20Notice) The company's board of directors, supervisory board, and senior management ensure the truthfulness, accuracy, and completeness of this semi-annual report, assuming legal responsibility, and the report details risks, countermeasures, and the 2025 semi-annual profit distribution plan - The company's 2025 semi-annual profit distribution plan is: based on 288,000,000 shares, no cash dividends will be distributed, no bonus shares will be issued, and capital reserves will be converted into 4.5 shares for every 10 shares to all shareholders[3](index=3&type=chunk) - The company's responsible person, chief financial officer, and head of accounting department all declare to guarantee the truthfulness, accuracy, and completeness of the financial report in this semi-annual report[3](index=3&type=chunk) [Definitions of Professional Terms](index=5&type=section&id=Definitions) This section defines key business, technical, and regulatory terms used in the report, including Active Pharmaceutical Ingredients (API), Non-Steroidal Anti-Inflammatory Drugs (NSAID), various drug registration certifications (e.g., CEP, DMF, cGMP), and Contract Development and Manufacturing Organization (CDMO) services, providing a foundation for understanding the company's business and industry background - The report explains several core pharmaceutical industry terms, such as Active Pharmaceutical Ingredients (API), Non-Steroidal Anti-Inflammatory Drugs (NSAID), current Good Manufacturing Practices (cGMP), and Contract Development and Manufacturing Organization (CDMO) services, which helps investors understand the company's business[12](index=12&type=chunk)[13](index=13&type=chunk) [Company Profile and Key Financial Indicators](index=8&type=section&id=Section%202.%20Company%20Profile%20and%20Key%20Financial%20Indicators) This section presents the company's fundamental information and key financial performance indicators for the reporting period [Company Basic Information](index=8&type=section&id=I.%20Company%20Profile) This section provides the company's basic registration information, including its stock abbreviation 'Hengdi Pharmaceutical', stock code '301211', full Chinese and English names, and legal representative, among other core identity details | Item | Content | | :--- | :--- | | Stock Abbreviation | Hengdi Pharmaceutical | | Stock Code | 301211 | | Listing Exchange | Shenzhen Stock Exchange | | Legal Representative | Cheng Zhigang | [Key Accounting Data and Financial Indicators](index=9&type=section&id=IV.%20Key%20Accounting%20Data%20and%20Financial%20Indicators) During the reporting period, the company experienced a significant performance decline, with operating revenue slightly decreasing by 2.93% year-on-year, while net profit attributable to shareholders plummeted by 72.92%, and non-recurring adjusted net profit sharply fell by 93.21%, with net cash flow from operating activities also decreasing by 73.71%, indicating considerable pressure on the company's profitability and cash flow | Indicator | Current Period | Prior Year Period | YoY Change | | :--- | :--- | :--- | :--- | | Operating Revenue(RMB) | 234,768,347.93 | 241,866,955.11 | -2.93% | | Net Profit Attributable to Parent(RMB) | 18,547,082.58 | 68,496,011.31 | -72.92% | | Non-recurring Adjusted Net Profit Attributable to Parent(RMB) | 4,416,152.74 | 65,041,920.42 | -93.21% | | Net Cash Flow from Operating Activities(RMB) | 8,401,294.23 | 31,957,787.67 | -73.71% | | Basic EPS(RMB/share) | 0.06 | 0.24 | -75.00% | | Weighted Average ROE | 0.80% | 2.95% | -2.15% | | Total Assets(RMB) | 2,392,174,132.73 | 2,488,655,694.01 | -3.88% (vs. Prior Year-End) | | Net Assets Attributable to Parent(RMB) | 2,256,889,033.97 | 2,309,688,533.16 | -2.29% (vs. Prior Year-End) | [Non-Recurring Gains and Losses Items and Amounts](index=9&type=section&id=VI.%20Non-Recurring%20Gains%20and%20Losses%20Items%20and%20Amounts) During the reporting period, the company's total non-recurring gains and losses amounted to RMB 14,130,900, significantly impacting net profit, primarily comprising RMB 14,854,300 in fair value changes from financial assets held and RMB 1,671,300 in government grants | Item | Amount(RMB) | | :--- | :--- | | Fair Value Change Gains/Losses from Financial Assets and Liabilities Held by Non-Financial Enterprises | 14,854,328.10 | | Government Grants Included in Current Period P&L | 1,671,322.76 | | **Total Non-Recurring Gains and Losses** | **14,130,929.84** | [Management Discussion and Analysis (MD&A)](index=11&type=section&id=Section%203.%20Management%20Discussion%20and%20Analysis%20(MD%26A)) This section provides a comprehensive analysis of the company's operations, financial condition, and future outlook, as discussed by management [Overview of Main Businesses](index=11&type=section&id=I.%20Main%20Businesses%20During%20the%20Reporting%20Period) The company primarily engages in the research, development, production, and sales of Active Pharmaceutical Ingredients (API) and preparations, also offering CDMO services, with core products including ibuprofen and other non-steroidal anti-inflammatory APIs, while also expanding into cardiovascular and anti-tumor fields; during the reporting period, the company achieved RMB 235 million in revenue, a 2.93% year-on-year decrease, and RMB 18.55 million in net profit, a significant 72.92% year-on-year decrease, with R&D investment of RMB 15.88 million, down 17.72% year-on-year, yet several new drug projects made progress - The company's main business involves the R&D, production, and sales of Active Pharmaceutical Ingredients (API) and preparations, as well as CDMO services, forming a product system centered on non-steroidal anti-inflammatory APIs, supplemented by specialty APIs for cardiovascular and anti-tumor applications[36](index=36&type=chunk) | Financial Indicator | Amount(RMB) | YoY Change | | :--- | :--- | :--- | | Operating Revenue | 234,768,347.93 | -2.93% | | Net Profit Attributable to Parent | 18,547,082.58 | -72.92% | | R&D Investment | 15,876,209.56 | -17.72% | - During the reporting period, products such as Ibuprofen Sustained-Release Capsules and Torasemide Injection obtained drug registration certificates, and multiple R&D projects progressed smoothly[42](index=42&type=chunk) [Analysis of Core Competencies](index=15&type=section&id=II.%20Analysis%20of%20Core%20Competencies) The company's core competencies are evident in four key areas: R&D, through continuous process innovation to reduce ibuprofen costs and expand specialty API product lines; Production, possessing modern, automated manufacturing capabilities and a stringent quality management system; Registration, with products certified by multiple countries' GMP standards and becoming qualified suppliers to international giants like Sanofi and GlaxoSmithKline; and the integrated 'API + Preparation' model, ensuring supply chain stability, cost advantages, and enhanced risk resilience - The company continuously innovates processes for ibuprofen API to reduce production costs, develops derivative products like dexibuprofen, and expands into specialty APIs for anti-tumor and cardiovascular applications[44](index=44&type=chunk)[45](index=45&type=chunk) - The company's main API products have passed GMP certifications and drug registrations in multiple countries and regions, including China, the United States, and the European Union, successfully entering the supply chains of global pharmaceutical giants such as Sanofi, GlaxoSmithKline, and Abbott[47](index=47&type=chunk) - The integrated "API + Preparation" layout is one of the company's core advantages, ensuring raw material supply, reducing preparation costs, and securing market position through cost and quality control in the context of centralized procurement[48](index=48&type=chunk)[49](index=49&type=chunk) [Analysis of Main Business](index=17&type=section&id=III.%20Analysis%20of%20Main%20Business) During the reporting period, the company's main business costs increased by 18.45%, primarily due to a decline in API product gross margin, leading the company to adopt a volume-for-value strategy; financial expenses significantly decreased by 85.51% mainly due to reduced interest income; by product segment, non-steroidal anti-inflammatory drugs remained the largest revenue source but saw both revenue and gross margin decline, while anti-tumor products' revenue grew by 42.67% but their gross margin turned negative at -11.32%, indicating cost control challenges | Financial Item | Current Period(RMB) | YoY Change | Reason for Change | | :--- | :--- | :--- | :--- | | Operating Cost | 183,347,719.02 | 18.45% | Gross margin of API products decreased, and the company increased sales volume to maintain sales revenue | | Financial Expenses | -6,011,409.88 | -85.51% | Interest income decreased in this period | | Income Tax Expense | 1,974,604.33 | -84.06% | Total profit decreased in this period | | Product Category | Operating Revenue(RMB) | Revenue YoY Change | Gross Margin | Gross Margin YoY Change | | :--- | :--- | :--- | :--- | :--- | | Non-Steroidal Anti-Inflammatory | 159,778,817.35 | -9.35% | 15.27% | -12.58% | | Cardiovascular | 37,760,622.99 | 14.57% | 71.83% | -5.20% | | Anti-Tumor | 16,419,201.42 | 42.67% | -11.32% | -35.59% | [Analysis of Assets and Liabilities](index=18&type=section&id=V.%20Analysis%20of%20Assets%20and%20Liabilities) As of the end of the reporting period, the company's total assets were RMB 2.392 billion, a 3.88% decrease from the beginning of the year, with no significant changes in asset composition; financial assets measured at fair value had an ending balance of RMB 1.039 billion, primarily trading financial assets (wealth management products), generating RMB 10.57 million in fair value change gains for the period; additionally, RMB 8.9 million in monetary funds were restricted as collateral - The company's financial assets measured at fair value are primarily trading financial assets (wealth management products), with an ending balance of approximately **RMB 1.03 billion**, generating **RMB 10.57 million** in fair value change gains for the current period[57](index=57&type=chunk)[58](index=58&type=chunk) - As of the end of the reporting period, **RMB 8.9 million** of the company's monetary funds were restricted as collateral[59](index=59&type=chunk) [Analysis of Investment Status](index=19&type=section&id=VI.%20Analysis%20of%20Investment%20Status) During the reporting period, the company's investment amounted to RMB 70 million, a significant 87.32% year-on-year decrease, with a cumulative utilization rate of 40.96% for raised funds; the company adjusted some fundraising projects, terminating the 'Annual Production of 5,000 Tons of Ibuprofen API Project' due to market oversupply and low prices, and extending the construction period for several other projects, including the 'High-End Pharmaceutical Preparation Internationalization Project' - Given the saturated supply and demand and low prices in the international ibuprofen API market, the company decided to terminate the "Annual Production of 5,000 Tons of Ibuprofen API Project" and reallocate part of the corresponding raised funds to other R&D and technical renovation projects[68](index=68&type=chunk) - Due to longer approval times and changes in market conditions, the company extended the estimated ready-for-use date for the "High-End Pharmaceutical Preparation Internationalization Project" to December 2026, and also extended two other API projects[67](index=67&type=chunk) [Risks and Countermeasures](index=25&type=section&id=X.%20Risks%20Faced%20by%20the%20Company%20and%20Countermeasures) The company identified five major operational risks: production safety (involving hazardous chemicals and high-temperature environments), product quality (high drug safety requirements), exchange rate fluctuations (overseas sales affected by RMB exchange rates), international trade environment (e.g., changes in China-India economic and trade relations), and pharmaceutical industry policy (e.g., centralized drug procurement); the company stated it will closely monitor and actively respond - The company faces multiple risks including production safety, product quality, exchange rate fluctuations, international trade environment, and industry policies[77](index=77&type=chunk)[78](index=78&type=chunk)[79](index=79&type=chunk)[81](index=81&type=chunk)[82](index=82&type=chunk) - Regarding international trade risks, one of the company's main raw material suppliers for isobutylbenzene is from India, and some ibuprofen products are also sold to India; changes in China-India economic and trade relations could adversely affect the company's operations[81](index=81&type=chunk) [Corporate Governance, Environment and Society (ESG)](index=26&type=section&id=Section%204.%20Corporate%20Governance%2C%20Environment%20and%20Society%20(ESG)) This section details the company's corporate governance practices, environmental initiatives, and social responsibility efforts [Profit Distribution and Capital Reserve Conversion](index=27&type=section&id=II.%20Profit%20Distribution%20and%20Capital%20Reserve%20to%20Share%20Capital%20Conversion%20in%20This%20Reporting%20Period) The company's 2025 semi-annual profit distribution plan proposes no cash dividends or bonus shares, but a capital reserve transfer of 4.5 shares for every 10 shares to all shareholders, based on a total share capital of 288,000,000 shares | Distribution/Conversion Item | Quantity | | :--- | :--- | | Bonus Shares per 10 Shares(Shares) | 0 | | Dividend per 10 Shares(RMB)(Tax Included) | 0 | | Capital Reserve Conversion per 10 Shares(Shares) | 4.5 | | Share Capital Base for Distribution Plan(Shares) | 288,000,000 | [Environmental Information Disclosure](index=28&type=section&id=IV.%20Environmental%20Information%20Disclosure) The company and its main subsidiaries have been included in the list of enterprises required to disclose environmental information by law, indicating their production and operation activities are under key supervision by environmental protection authorities, and the company must publicly disclose its environmental information as required - Hubei Hengdi Pharmaceutical Co., Ltd. has been included in the list of enterprises required to disclose environmental information by law[89](index=89&type=chunk) [Social Responsibility](index=28&type=section&id=V.%20Social%20Responsibility) The company has implemented various social responsibility measures, including protecting investor rights, caring for employees, safeguarding customer interests, and emphasizing environmental protection; the company promotes a 'low-carbon, energy-saving, green, and healthy' philosophy, achieving clean production through technological transformation and full-process control, and entrusting qualified third parties to handle its 'three wastes', with no environmental violations or irregularities reported during the period - The company emphasizes environmental protection, entrusting qualified third parties to handle its "three wastes" and strictly adhering to emission standards, with no environmental pollution incidents occurring during the reporting period[92](index=92&type=chunk) [Significant Matters](index=30&type=section&id=Section%205.%20Significant%20Matters) This section highlights significant events and commitments during the reporting period, including their fulfillment status [Fulfillment of Commitments](index=30&type=section&id=I.%20Fulfillment%20of%20Commitments%20by%20Controlling%20Shareholders%2C%20Shareholders%2C%20Related%20Parties%2C%20Acquirers%20and%20the%20Company) During the reporting period, all commitments made by the company's related parties during its initial public offering, including share lock-up and share price stabilization, were fulfilled, with no overdue unfulfilled commitments - The company's controlling shareholder, actual controller, directors, supervisors, and senior management, among other related parties, have fulfilled their share lock-up commitments and IPO share price stabilization commitments made during the initial public offering[95](index=95&type=chunk)[96](index=96&type=chunk) [Other Significant Matters](index=38&type=section&id=Other%20Significant%20Matters) During the reporting period, the company had no significant matters requiring special disclosure, such as non-operating fund occupation by controlling shareholders, illegal external guarantees, major litigation or arbitration, significant related-party transactions, or major contracts - During the reporting period, the company had no instances of controlling shareholder fund occupation, illegal guarantees, major litigation, or significant related-party transactions[104](index=104&type=chunk)[105](index=105&type=chunk)[107](index=107&type=chunk)[108](index=108&type=chunk)[121](index=121&type=chunk) [Share Changes and Shareholder Information](index=42&type=section&id=Section%206.%20Share%20Changes%20and%20Shareholder%20Information) This section outlines changes in the company's share capital and provides details on its shareholder structure [Share Change Status](index=42&type=section&id=I.%20Share%20Change%20Status) During the reporting period, the company's total share capital of 288,000,000 shares remained unchanged, with the main change being the lifting of restrictions on 216,000,000 pre-IPO restricted shares, representing 75% of the total share capital, converting them into unrestricted shares - During the reporting period, **216,000,000** restricted shares of the company were released from lock-up, accounting for **75.00%** of the company's total share capital, increasing the proportion of unrestricted shares from **25%** to **100%**[126](index=126&type=chunk)[127](index=127&type=chunk) [Number of Shareholders and Shareholding Status](index=44&type=section&id=III.%20Number%20of%20Shareholders%20and%20Shareholding%20Status) As of the end of the reporting period, the company had a total of 17,134 common shareholders, with the top three being Shanghai Yongdasheng Business Consulting Co., Ltd. (38.25% stake), Liu Tianchao (12.00% stake), and Jingmen Ningkang Enterprise Management Center (Limited Partnership) (5.63% stake) - As of the end of the reporting period, the company had a total of **17,134** shareholders[130](index=130&type=chunk) | Shareholder Name | Shareholding Percentage | Number of Shares Held | | :--- | :--- | :--- | | Shanghai Yongdasheng Business Consulting Co., Ltd. | 38.25% | 110,160,000 | | Liu Tianchao | 12.00% | 34,560,000 | | Jingmen Ningkang Enterprise Management Center (Limited Partnership) | 5.63% | 16,200,000 | [Financial Report](index=49&type=section&id=Section%208.%20Financial%20Report) This section contains the audited financial statements, key accounting policies, and detailed notes to the financial statements [Audit Report](index=49&type=section&id=I.%20Audit%20Report) This semi-annual financial report has been audited by Daxin Certified Public Accountants (Special General Partnership), which issued a standard unqualified audit opinion (Daxin Audit [2025] No. 2-01167) - The company's 2025 semi-annual financial report was audited by Daxin Certified Public Accountants, which issued a standard unqualified opinion[138](index=138&type=chunk) [Financial Statements](index=49&type=section&id=II.%20Financial%20Statements) This section provides the company's consolidated and parent company balance sheets, income statements, cash flow statements, and statements of changes in owners' equity for the first half of 2025, serving as core bases for analyzing the company's financial position, operating results, and cash flows - The consolidated and parent company balance sheets as of June 30, 2025, and the income statements, cash flow statements, and statements of changes in owners' equity for the first half of 2025 are provided[138](index=138&type=chunk)[142](index=142&type=chunk)[145](index=145&type=chunk)[150](index=150&type=chunk)[155](index=155&type=chunk) [Significant Accounting Policies and Estimates](index=67&type=section&id=V.%20Significant%20Accounting%20Policies%20and%20Estimates) This section elaborates on the company's fundamental accounting principles, accounting period, and functional currency, and highlights significant accounting policies such as revenue recognition, financial instruments, long-term equity investments, and fixed assets; during the reporting period, the company made a significant change in accounting estimates, adjusting the capitalization point for R&D expenditures to more accurately reflect the value of R&D investments - On April 23, 2025, the company changed its accounting estimate for the capitalization point of R&D expenditures; after the change, expenditures for drugs requiring clinical trials are capitalized after entering Phase III clinical trials, and for other drugs, expenditures are capitalized after obtaining human bioequivalence clinical filing; this change resulted in an increase of **RMB 623,600.00** in development expenditures and a corresponding decrease in R&D expenses[240](index=240&type=chunk)[241](index=241&type=chunk) [Notes to Consolidated Financial Statements](index=84&type=section&id=VII.%20Notes%20to%20Consolidated%20Financial%20Statements) This section provides detailed notes on key items in the consolidated financial statements, including: ending monetary funds of RMB 540 million, of which RMB 8.9 million is restricted; trading financial assets (wealth management products) of RMB 1.03 billion; accounts receivable ending balance of RMB 76.03 million, with a bad debt provision of RMB 7.81 million; inventory of RMB 116 million, with an impairment provision of RMB 2.03 million; and major construction in progress projects primarily being the High-End Pharmaceutical Preparation Internationalization Project and the Ibuprofen Technical Renovation Project - Ending trading financial assets amounted to **RMB 1.03 billion**, primarily consisting of bank wealth management products[248](index=248&type=chunk) - The top five accounts receivable balances at period-end totaled **RMB 18.48 million**, accounting for **24.30%** of the total[261](index=261&type=chunk) - Significant construction in progress projects include the "High-End Pharmaceutical Preparation Internationalization Project" with a budget of **RMB 332 million** and the "Ibuprofen API Wastewater Hydrolysis Acidification Project" with a budget of **RMB 86 million**[296](index=296&type=chunk) [Supplementary Information](index=117&type=section&id=XVI.%20Supplementary%20Information) This section provides a detailed statement of non-recurring gains and losses and calculations for return on net assets and earnings per share; during the reporting period, non-recurring gains and losses totaled RMB 14.13 million, primarily from fair value changes of financial assets; after deducting non-recurring gains and losses, net profit attributable to common shareholders was RMB 4.42 million, weighted average return on net assets decreased to 0.19%, and basic earnings per share was RMB 0.020 | Profit for the Period | Weighted Average ROE | Basic EPS(RMB/share) | | :--- | :--- | :--- | | Net Profit Attributable to Common Shareholders of the Company | 0.80% | 0.06 | | Net Profit Attributable to Common Shareholders of the Company After Deducting Non-Recurring Gains and Losses | 0.19% | 0.020 |

证券代码：688011 证券简称：新光光电 公告编号：2025-022 哈尔滨新光光电科技股份有限公司 2025 年半年度业绩预亏公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 6 月 30 日。 （二）业绩预告情况 （1）经财务部门初步测算，预计 2025 年半年度公司实现营业收入约 2,100.00 万元，实现归属于上市公司股东的净利润将出现亏损，预计实现归属 于上市公司股东的净利润为-1,900.00 万元到-2,300.00 万元，同比下降 6.35% 到 28.74%。 二、上年同期业绩情况 归属于上市公司股东的净利润：-1,786.57 万元。归属于上市公司股东的扣 除非经常性损益的净利润：-2,576.85 万元。 三、本期业绩预亏的主要原因 报告期内,公司营业收入约 2,100 万元，同比下降约 59.31%，实现归属于上 市公司股东的净利润将出现亏损，同比下降约 6.35%到 28.74%。报告期营业收入 下降 ...

道道全粮油股份有限公司 2025 年半年度报告全文 道道全粮油股份有限公司 2025 年半年度报告 2025-037 【2025 年 08 月】 1 道道全粮油股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人刘建军、主管会计工作负责人李小平及会计机构负责人(会计 主管人员)胡怡兵声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 公司经本次董事会审议通过的利润分配预案为：以 343,968,305 为基数， 向全体股东每 10 股派发现金红利 1.76 元（含税），送红股 0 股（含税）， 不以公积金转增股本。 2 | 目录 | | --- | | 第一节 重要提示、目录和释义 | 2 | | --- | --- | | 第二节 公司简介和主要财务指标 | 6 | | 第三节 管理层讨论与分析 | 9 | | 第四节 公司治理、环境和社会 | 25 | | 第五节 重要事项 ...

新疆汇嘉时代百货股份有限公司2025 年半年度报告 公司代码：603101 公司简称：汇嘉时代 新疆汇嘉时代百货股份有限公司 2025 年半年度报告 1 / 144 新疆汇嘉时代百货股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人朱翔、主管会计工作负责人范新萍及会计机构负责人（会计主管人员）邹明友 声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 本报告期，公司无利润分配及资本公积金转增股本预案。 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者的实质承诺，敬请 投资者注意投资风险。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况 否 九、 是否存在半数以上董事无法保证公司所披露 ...

2025 年半年度报告全文 深圳顺络电子股份有限公司 2025 年半年度报告 2025 年 7 月 1 2025 年半年度报告全文 董事会致辞 尊敬的各位股东： 2025 年上半年，公司全体员工齐心协力，践行业务发展目标，经营业绩逐季连创历史 同期新高，其中 2025 年第二季度单季度营收实现人民币 17.63 亿元，创单季度营收历史新 高。2025 年上半年实现营收人民币 32.24 亿元，归属上市公司股东净利润人民币 4.86 亿元， 创半年度历史新高。 2025 年第二季度，公司于手机通讯、消费电子等传统市场应用领域保持了稳步成长， 在 AI+应用、汽车电子、数据中心等新兴战略市场实现了持续强劲的高速增长。在复杂多 变的经营环境下，公司的创新业务蓬勃发展，新产品得到多位全球顶级科技客户的认可， 其中数据中心业务于 2025 年上半年实现订单的重要增长，成为公司继汽车电子市场之后 又一新兴战略市场的标志性突破。 公司将坚持从传统"产品提供者"向"价值创造者"转型。随着 AI+应用赋能全行业， 各种应用场景的电子智能终端飞速发展，我们持续坚持市场洞察工作，主动预见客户需求， 抓住新兴市场机遇，持续加大基础技 ...

深圳市智微智能科技股份有限公司 2025 年半年度报告全文 深圳市智微智能科技股份有限公司 2025 年半年度报告 2025.07 1 深圳市智微智能科技股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人袁微微、主管会计工作负责人李敏及会计机构负责人(会计主 管人员)李敏声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本报告中涉及的未来发展陈述，属于计划性事项，不构成公司对投资者的 实质承诺，敬请投资者及相关人士均应当对此保持足够的风险认识，并且应 当理解计划、预测与承诺之间的差异，注意投资风险。 公司在本报告第三节"管理层讨论与分析"之"十、公司面临的风险和应 对措施"部分详细描述了公司未来经营中可能存在的风险及应对措施，敬请 投资者关注相关内容。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | | | | 第一节 | 重要提示、目录和释义 | 2 | ...